GU Cancers 2020 | ATLAS update: rucaparib for bladder cancer

Name: ATLAS update: rucaparib for bladder cancer
Uploaded: 2020-02-16T13:59:35Z
Description: Petros Grivas, MD, PhD, University of Washington, Seattle, WA, outlines the ATLAS study (NCT03397394), which investigated the efficacy of the PARP inhibitor rucaparib in the treatment of urothelial carcinoma. This interview was recorded at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Petros Grivas • 16 Feb 2020

GU Cancers 2020

Bladder Cancer Genitourinary Cancer Rucaparib

ATLAS

Petros Grivas, MD, PhD, University of Washington, Seattle, WA, outlines the ATLAS study (NCT03397394), which investigated the efficacy of the PARP inhibitor rucaparib in the treatment of urothelial carcinoma. This interview was recorded at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.